OPKO Health, Inc. (OPK)
NASDAQ: OPK · Real-Time Price · USD
1.460
-0.010 (-0.68%)
At close: Oct 11, 2024, 4:00 PM
1.480
+0.020 (1.37%)
After-hours: Oct 11, 2024, 6:52 PM EDT

Company Description

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally.

The company’s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency.

This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia.

In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others.

The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 2007 and is headquartered in Miami, Florida.

OPKO Health, Inc.
OPKO Health logo
Country United States
Founded 2007
IPO Date Nov 2, 1995
Industry Diagnostics & Research
Sector Healthcare
Employees 3,930
CEO Phillip Frost

Contact Details

Address:
4400 Biscayne Boulevard
Miami, Florida 33137
United States
Phone 305 575 4100
Website opko.com

Stock Details

Ticker Symbol OPK
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000944809
CUSIP Number 68375N103
ISIN Number US68375N1037
Employer ID 75-2402409
SIC Code 2834

Key Executives

Name Position
Dr. Charles W. Bishop Chief Executive Officer of OPKO Renal
Dr. Phillip Frost Ph.D. Chairman and Chief Executive Officer
Dr. Jane H. Hsiao M.B.A., Ph.D. Vice Chairman and Chief Technical Officer
Dr. Elias Adam Zerhouni M.D. President and Vice Chairman
Adam E. Logal Senior Vice President, Chief Financial Officer, Chief Accounting Officer and Treasurer
Steven D. Rubin Esq., J.D. Executive Vice President of Administration and Director
Dr. Akhtar Ashfaq FACP, FASN, M.D. Senior Vice President of Clinical Research and Development and Medical Affairs - Opko Renal
Dr. Gary J. Nabel M.D., Ph.D. Chief Innovation Officer and Director
Dr. Antonio F. Cruz President of Transition Therapeutics
Hans Berner President of OPKO Health Iberoamerica

Latest SEC Filings

Date Type Title
Sep 16, 2024 8-K Current Report
Aug 30, 2024 DEFR14A Filing
Aug 29, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Aug 19, 2024 4 Statement of changes in beneficial ownership of securities
Aug 14, 2024 4 Statement of changes in beneficial ownership of securities
Aug 8, 2024 4 Statement of changes in beneficial ownership of securities
Aug 7, 2024 10-Q Quarterly Report
Aug 7, 2024 8-K Current Report
Aug 2, 2024 4 Statement of changes in beneficial ownership of securities
Jul 31, 2024 4 Statement of changes in beneficial ownership of securities